January 22, 2016

Securities and Exchange Commission
450 Fifth Street NW
Washington, DC 20549

RE: Schedule 13G
Acorda Therapeutics, Inc.
As of December 31, 2015

Gentlemen:

In accordance with Section 13(d)(5) of the Securities Exchange Act of 1934, attached please find a copy of Schedule 13G for the above named company showing beneficial ownership as of December 31, 2015 filed on behalf of Eagle Asset Management, Inc.

Very truly yours,

Damian Sousa
Vice President
Chief Compliance Officer
DS:cc
Enclosures

cc: Office of the Corporate Secretary Acorda Therapeutics, Inc.
420 Saw Mill River Road
Ardsley, NY 10502

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Schedule 13G

Under the Securities Exchange Act of 1934

(Amendment No. 2 )*

Acorda Therapeutics, Inc.
(Name of Issuer)

Common Stock
(Title of Class of Securities)

00484M106
(CUSIP Number)

Check the following box if a fee is being paid with this statement _____. (A fee is not required only if the filing person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 5 Pages

CUSIP NO. 00484M106                                 13G

 1  NAME OF REPORTING PERSON
    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
      Eagle Asset Management, Inc.      59-2385219

 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*  (A) ______
                                                      (B) ______

 3  SEC USE ONLY

 4 CITIZENSHIP OR PLACE OF ORGANIZATION

   State of Florida

        NUMBER OF             5   SOLE VOTING POWER
         SHARES                           1,788,358
      BENEFICIALLY            6   SHARED VOTING POWER
         OWNED                             - - -
         AS OF
    DECEMBER 31, 2015         7  SOLE DISPOSITIVE POWER
        BY EACH                           1,788,358
       REPORTING              8   SHARED DISPOSITIVE POWER
      PERSON WITH                      - - -

 9  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

             1,788,358

10    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
                                                  [_____]

11  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

              4.14%

12  TYPE OF REPORTING PERSON*

            IA
_____________________________________________________________
                 *SEE INSTRUCTION BEFORE FILLING OUT!
_____________________________________________________________

Page 2 of 5 Pages
Item 1(a)       Name of Issuer:

                Acorda Therapeutics, Inc.


Item 1(b)       Address of Issuer's Principal Executing Offices:

                420 Saw Mill River Road
                Ardsley, NY 10502


Item 2(a)       Name of Person Filing:

                Eagle Asset Management, Inc.


Item 2(b)       Address of Principal Business Office:

                880 Carillon Parkway
                St. Petersburg, Florida  33716


Item 2(c)       Citizenship:

                Florida


Item 2(d)       Title of Class of Securities:

                Common Stock


Item 2(e)       CUSIP Number:

                00484M106


Item 3          Type of Reporting Person:

(e) Investment  Adviser  registered  under Section 203 of the Investment
Advisors Act of 1940



Page 3 of 5 Pages
Item 4          Ownership as of December 31, 2015

         (a)    Amount Beneficially Owned:

                1,788,358 shares of common stock beneficially owned including:

                 No. of Shares
                 Eagle Asset Management, Inc.                   1,788,358

          (b)   Percent of Class:                               4.14%


         (c)    Deemed Voting Power and Disposition Power:

                (i)             (ii)                (iii)         (iv)
                                                  Deemed          Deemed
                Deemed         Deemed             to have         to have
                to have        to have            Sole Power      Shared Power
                Sole Power     Shared Power       to Dispose      to Dispose
                to Vote or     to Vote or         or to           or to
                to Direct      to Direct          Direct the      Direct the
                to Vote        to Vote            Disposition     Disposition

Eagle Asset     1,788,358       ----              1,788,358        ----
Management, Inc.


Item 5          Ownership of Five Percent or Less of a Class:

                 If  this  statement is being filed to report the  fact that
as of the date hereof the reporting person has ceased to  be the  beneficial
owner of more than five percent of the  class  of securities, check the
following.
                (x)

Item 6          Ownership of More than Five Percent on Behalf of Another Person:

                 N/A

Item 7          Identification and Classification of the Subsidiary which Acquired
                the Security Being Reported on by the Parent Holding Company:

                 N/A

Page 4 of 5 Pages
Item 8          Identification and Classification of  Members  of the Group:   N/A


Item 9          Notice of Dissolution of Group:   N/A


Item 10         Certification:

                By  signing  below I certify that to the  best  of  my
knowledge  and  belief,  the securities referred  to  above  were acquired
in the ordinary course of business and were not acquired for  purpose  of
and  do  not have the  effect  of  changing  or influencing the control of
the issuer of such securities and were not  acquired  in  connection with
or as  a  participant  in  any transaction having such purposes or effect.

                Signature


         After  reasonable  inquiry  and  to  the  best  of  my knowledge
and belief, I certify that the information set forth in this statement is
true, complete and correct.

Date: January 22, 2016                  EAGLE ASSET MANAGEMENT, INC.


                                        /s/ Damian Sousa
                                        _________________________________
                                        Damian Sousa
                                        Vice President
                                        Chief Compliance Officer





Page 5 of 5 Pages

Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Acorda Therapeutics Charts.
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Acorda Therapeutics Charts.